Latest Insider Transactions at Travere Therapeutics, Inc. (TVTX)
This section provides a real-time view of insider transactions for Travere Therapeutics, Inc. (TVTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Travere Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Travere Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 04
2024
|
Gary A Lyons |
SELL
Open market or private sale
|
Direct |
40,000
-25.11%
|
$560,000
$14.75 P/Share
|
|
Oct 04
2024
|
Gary A Lyons |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+30.53%
|
$400,000
$10.48 P/Share
|
|
Sep 30
2024
|
Jeffrey A Meckler |
SELL
Open market or private sale
|
Direct |
40,000
-33.06%
|
$560,000
$14.06 P/Share
|
|
Sep 30
2024
|
Jeffrey A Meckler |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+24.84%
|
$400,000
$10.48 P/Share
|
|
Sep 10
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
684
-1.09%
|
$8,208
$12.98 P/Share
|
|
Sep 09
2024
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,490
-3.23%
|
$27,390
$11.52 P/Share
|
|
Sep 09
2024
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,191
-1.99%
|
$24,101
$11.52 P/Share
|
|
Sep 09
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,191
-3.38%
|
$24,101
$11.52 P/Share
|
|
Sep 09
2024
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
21,125
-5.51%
|
$232,375
$11.52 P/Share
|
|
Sep 09
2024
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
4,387
-5.28%
|
$48,257
$11.52 P/Share
|
|
Sep 09
2024
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
4,387
-4.94%
|
$48,257
$11.52 P/Share
|
|
Sep 05
2024
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,750
+8.05%
|
-
|
|
Sep 05
2024
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,750
+5.77%
|
-
|
|
Sep 05
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
6,750
+9.43%
|
-
|
|
Sep 05
2024
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+7.82%
|
-
|
|
Sep 05
2024
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
6,750
+7.52%
|
-
|
|
Sep 05
2024
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
6,750
+7.06%
|
-
|
|
Sep 04
2024
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
514
-0.73%
|
$4,626
$9.51 P/Share
|
|
May 08
2024
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+17.33%
|
-
|
|
May 08
2024
|
Suzanne Louise Bruhn |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+22.61%
|
-
|
|
May 08
2024
|
Timothy Coughlin |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+11.71%
|
-
|
|
May 08
2024
|
Gary A Lyons |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+11.3%
|
-
|
|
May 08
2024
|
Jeffrey A Meckler |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+7.43%
|
-
|
|
May 08
2024
|
Sandra Poole |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+21.67%
|
-
|
|
May 08
2024
|
Brinkley Ruth Williams |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+25.24%
|
-
|
|
May 08
2024
|
John A Orwin |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+18.37%
|
-
|
|
May 08
2024
|
Ron Squarer |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+18.37%
|
-
|
|
Apr 11
2024
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
54
-0.08%
|
$324
$6.74 P/Share
|
|
Feb 01
2024
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,818
-5.11%
|
$30,544
$8.53 P/Share
|
|
Feb 01
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,174
-3.61%
|
$17,392
$8.53 P/Share
|
|
Feb 01
2024
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,195
-4.05%
|
$33,560
$8.53 P/Share
|
|
Feb 01
2024
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
4,764
-2.98%
|
$38,112
$8.7 P/Share
|
|
Feb 01
2024
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
2,820
-5.14%
|
$22,560
$8.53 P/Share
|
|
Feb 01
2024
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
4,764
-2.83%
|
$38,112
$8.7 P/Share
|
|
Feb 01
2024
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
19,122
-2.62%
|
$152,976
$8.7 P/Share
|
|
Jan 31
2024
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+25.07%
|
-
|
|
Jan 31
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+29.33%
|
-
|
|
Jan 31
2024
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+19.43%
|
-
|
|
Jan 31
2024
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+23.58%
|
-
|
|
Jan 31
2024
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+10.32%
|
-
|
|
Jan 31
2024
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+22.63%
|
-
|
|
Jan 31
2024
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+26.75%
|
-
|
|
Jan 23
2024
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,559
-1.94%
|
$14,031
$9.07 P/Share
|
|
Jan 23
2024
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
910
-2.15%
|
$8,190
$9.07 P/Share
|
|
Jan 23
2024
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,062
-3.3%
|
$16,496
$8.96 P/Share
|
|
Jan 23
2024
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
853
-1.69%
|
$7,677
$9.07 P/Share
|
|
Jan 23
2024
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,873
-3.25%
|
$62,984
$8.96 P/Share
|
|
Jan 23
2024
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,062
-3.55%
|
$16,496
$8.96 P/Share
|
|
Jan 04
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
440
-1.23%
|
$3,960
$9.17 P/Share
|
|
Jan 03
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,069
-5.48%
|
$18,621
$9.48 P/Share
|